Table 1.

Parameters used in the model

Base caseRange for DSADistribution for PSA
LowHigh
Japanese cost (in JPY)      
 Bortezomib 1.7 mg/m2 138 704 69 352 208 056 γ 
 Lenalidomide 25 mg 40 427 20 213 60 640 γ 
 Thalidomide 100 mg per body 6 883 3 442 10 325  
 Daratumumab 16 mg/kg 480 464 240 232 720 696 γ 
 Carfilzomib 20 mg/m2 87 852 43 926 131 778 γ 
 27 mg/m2 112  278 56 139 168  417 γ 
 56 mg/m2 263 556 131 778 395  334 γ 
 Pomalidomide 4 mg 61  669 30  835 92  504 γ 
 Panobinostat 20 mg 74 523 37  261 111  784 γ 
 Dexamethasone 20 mg 861 430 1 291 γ 
 Autologous transplantation 3 mo 4  515 479 2 257  740 6  773  219 γ 
 Elotuzumab 10 mg/kg 326  690 163 345 490  035 γ 
 Outpatient supportive care (on treatment) 3 mo 76 620 38 310 114  930 γ 
 Outpatient supportive care (off treatment) 3 mo 30  710 15 355 46  065 γ 
 Palliative care (including hospice care) 3 mo 1 753 014 876 507 2  629 521 γ 
US cost (in USD)      
 Bortezomib 1.7 mg/m2 1 503 752 2 255 γ 
 Lenalidomide 25 mg 736 368 1 104 γ 
 Thalidomide 100 mg per body 214 107 321  
 Daratumumab 16 mg/kg 6 497 3 249 9 746 γ 
 Carfilzomib 20 mg/m2 1 971 986 2 957 γ 
 27 mg/m2 1 971 986 2 957 γ 
 56 mg/m2 3 943 1 972 5 915 γ 
 Pomalidomide 4 mg 842 421 1 262 γ 
 Panobinostat 20 mg 1 222 611 1 833 γ 
 Dexamethasone 20 mg 861 430 1 291 γ 
 Autologous transplantation 3 mo 60 000 30  000 90  000 γ 
 Elotuzumab 10 mg/kg 4 736 2 368 7 104 γ 
 Outpatient supportive care (on treatment) 3 mo 1 656 828 2 483 γ 
 Outpatient supportive care (off treatment) 3 mo 341 171 512 γ 
 Palliative care (including hospice care) 3 mo 47 610 23  805 71  415 γ 
Utilities      
 First line  0.659 0.494 0.824 β 
 Maintenance  0.833 0.625 1.000 β 
 Second line  0.62 0.465 0.775 β 
 Third line  0.606 0.455 0.758 β 
 Fourth line or BSC  0.494 0.371 0.618 β 
Probabilities      
 MRD-negative (RVd)  0.204 0.153 0.255 β 
 MRD-negative (D-RVd)  0.5 0.375 0.625 β 
 MRD-negative (VTd)  0.37 0.278 0.463 β 
 MRD-negative (D-VTd)  0.57 0.428 0.713 β 
 PFS, second line, Dkd  0.925 0.897 0.953 β 
 PFS, second line, Kd  0.87 0.844 0.896 β 
 PFS, second line KRd  0.928 0.900 0.956  
 PFS, MRD-positive Cycle 1-5 0.96 0.931 0.989 β 
 Cycle 6-12 0.92 0.892 0.948 β 
 Cycle 13- 0.95 0.922 0.979 β 
 PFS, MRD-negative Cycle 1-5, 13- 0.99 0.960 1.000 β 
 Cycle 6-12 0.98 0.951 1.000 β 
 PFS, third-line, EloPd Cycle 1-2 0.775 0.752 0.798 β 
 Cycle 3- 0.904 0.877 0.931 β 
 PFS, fourth-line, Panobinostat+BD Cycle 1-4 0.84 0.815 0.865 β 
 Cycle 5- 0.65 0.631 0.670 β 
 Withdrawal from 2nd line  0.06 0 0.5 β 
 Withdrawal from 3rd line  0.15 0 0.5 β 
 Withdrawal from 4th line  0.2 0 0.5 β 
 Death as a PD event  0.1 0 0.2 β 
Base caseRange for DSADistribution for PSA
LowHigh
Japanese cost (in JPY)      
 Bortezomib 1.7 mg/m2 138 704 69 352 208 056 γ 
 Lenalidomide 25 mg 40 427 20 213 60 640 γ 
 Thalidomide 100 mg per body 6 883 3 442 10 325  
 Daratumumab 16 mg/kg 480 464 240 232 720 696 γ 
 Carfilzomib 20 mg/m2 87 852 43 926 131 778 γ 
 27 mg/m2 112  278 56 139 168  417 γ 
 56 mg/m2 263 556 131 778 395  334 γ 
 Pomalidomide 4 mg 61  669 30  835 92  504 γ 
 Panobinostat 20 mg 74 523 37  261 111  784 γ 
 Dexamethasone 20 mg 861 430 1 291 γ 
 Autologous transplantation 3 mo 4  515 479 2 257  740 6  773  219 γ 
 Elotuzumab 10 mg/kg 326  690 163 345 490  035 γ 
 Outpatient supportive care (on treatment) 3 mo 76 620 38 310 114  930 γ 
 Outpatient supportive care (off treatment) 3 mo 30  710 15 355 46  065 γ 
 Palliative care (including hospice care) 3 mo 1 753 014 876 507 2  629 521 γ 
US cost (in USD)      
 Bortezomib 1.7 mg/m2 1 503 752 2 255 γ 
 Lenalidomide 25 mg 736 368 1 104 γ 
 Thalidomide 100 mg per body 214 107 321  
 Daratumumab 16 mg/kg 6 497 3 249 9 746 γ 
 Carfilzomib 20 mg/m2 1 971 986 2 957 γ 
 27 mg/m2 1 971 986 2 957 γ 
 56 mg/m2 3 943 1 972 5 915 γ 
 Pomalidomide 4 mg 842 421 1 262 γ 
 Panobinostat 20 mg 1 222 611 1 833 γ 
 Dexamethasone 20 mg 861 430 1 291 γ 
 Autologous transplantation 3 mo 60 000 30  000 90  000 γ 
 Elotuzumab 10 mg/kg 4 736 2 368 7 104 γ 
 Outpatient supportive care (on treatment) 3 mo 1 656 828 2 483 γ 
 Outpatient supportive care (off treatment) 3 mo 341 171 512 γ 
 Palliative care (including hospice care) 3 mo 47 610 23  805 71  415 γ 
Utilities      
 First line  0.659 0.494 0.824 β 
 Maintenance  0.833 0.625 1.000 β 
 Second line  0.62 0.465 0.775 β 
 Third line  0.606 0.455 0.758 β 
 Fourth line or BSC  0.494 0.371 0.618 β 
Probabilities      
 MRD-negative (RVd)  0.204 0.153 0.255 β 
 MRD-negative (D-RVd)  0.5 0.375 0.625 β 
 MRD-negative (VTd)  0.37 0.278 0.463 β 
 MRD-negative (D-VTd)  0.57 0.428 0.713 β 
 PFS, second line, Dkd  0.925 0.897 0.953 β 
 PFS, second line, Kd  0.87 0.844 0.896 β 
 PFS, second line KRd  0.928 0.900 0.956  
 PFS, MRD-positive Cycle 1-5 0.96 0.931 0.989 β 
 Cycle 6-12 0.92 0.892 0.948 β 
 Cycle 13- 0.95 0.922 0.979 β 
 PFS, MRD-negative Cycle 1-5, 13- 0.99 0.960 1.000 β 
 Cycle 6-12 0.98 0.951 1.000 β 
 PFS, third-line, EloPd Cycle 1-2 0.775 0.752 0.798 β 
 Cycle 3- 0.904 0.877 0.931 β 
 PFS, fourth-line, Panobinostat+BD Cycle 1-4 0.84 0.815 0.865 β 
 Cycle 5- 0.65 0.631 0.670 β 
 Withdrawal from 2nd line  0.06 0 0.5 β 
 Withdrawal from 3rd line  0.15 0 0.5 β 
 Withdrawal from 4th line  0.2 0 0.5 β 
 Death as a PD event  0.1 0 0.2 β 

DSA, deterministic sensitivity analysis; JPY, Japanese yen; PD, progressive disease; USD, US dollars.

Drug costs are shown as costs per administration. Probabilities for PFS means per cycle probabilities of maintaining PFS.

View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal